TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35986579

Group type: EXPERIMENTAL
Intervention: Brief, supported eTherapy (four-session program)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Program feasibility
Number of subjects: 19
Study: 36254133

Group type: EXPERIMENTAL
Intervention: Real tPBM (5 sessions of 850 nm)
Number of subjects: 42
Study: 32482519

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg SR orally twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 34968119

Group type: EXPERIMENTAL
Intervention: Multicomponent positive psychology intervention
Number of subjects: 141

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 141
Study: 34028623

Group type: EXPERIMENTAL
Intervention: All-inside tibial socket preparation (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Complete tibial tunnel technique (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quadrupled semitendinosus tendon graft
Number of subjects: 80
Study: 32585354

Group type: EXPERIMENTAL
Intervention: HD BP BL ECT
Number of subjects: 0
Study: 34397389

Group type: EXPERIMENTAL
Intervention: IMP‐FITNET
Number of subjects: 244

Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 244
Study: 34709880

Group type: EXPERIMENTAL
Intervention: Response-adapted postinduction approach
Number of subjects: 807

Group type: COMPARATOR
Intervention: Standard rituximab maintenance (RM)
Number of subjects: 807
Study: 34768520

Group type: EXPERIMENTAL
Intervention: Myofascial induction therapy (MIT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (simulated pulsed shortwave therapy)
Number of subjects: 22
Study: 34218684

Group type: EXPERIMENTAL
Intervention: Repeated ivermectin mass drug administrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized estimating equations with small sample corrections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crossover design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster-level analyses and individual-level analyses
Number of subjects: 0
Study: 32600389

Group type: EXPERIMENTAL
Intervention: 1 mg/d folic acid
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 36142006

Group type: EXPERIMENTAL
Intervention: Mantra meditation alone (MA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Meditation plus physical yoga (MY)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Meditation plus ethical education (ME)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Meditation plus yoga and ethical education (MYE)
Number of subjects: 42
Study: 34666808

Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen (HFNO) with FiO2 0.35, flow 50 LPM, temperature 34 °C
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low flow nasal oxygen (LFNO) 5 LPM
Number of subjects: 22
Study: 35020026

Group type: EXPERIMENTAL
Intervention: Allogeneic growth factors
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study: 34547824

Group type: EXPERIMENTAL
Intervention: Screw-retained crowns
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cemented crowns
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 35715450

Group type: EXPERIMENTAL
Intervention: Citalopram (a selective-serotonin-reuptake inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32628258

Group type: EXPERIMENTAL
Intervention: ACP video program
Number of subjects: 9935

Group type: COMPARATOR
Intervention: Control (usual ACP practices)
Number of subjects: 9935
Study: 34606832

Group type: EXPERIMENTAL
Intervention: 1.0% asivatrep cream
Number of subjects: 240

Group type: COMPARATOR
Intervention: Vehicle group
Number of subjects: 240
Study: 33631066

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg, single intravenous infusion, with a possible second dose 8 to 24 hours later)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 438
Study: 32762672

Group type: EXPERIMENTAL
Intervention: Low-dose exogenous surfactant (20 mg/kg)
Number of subjects: 44
Study: 35188554

Group type: EXPERIMENTAL
Intervention: Guideline implementation strategies at the cluster, health professional, and patient levels
Number of subjects: 688

Group type: COMPARATOR
Intervention: Control phase (no intervention)
Number of subjects: 688
Study: 32810929

Group type: EXPERIMENTAL
Intervention: Awareness of breast density (non-dense breast)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Awareness of breast density (dense breast)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Good breast density knowledge
Number of subjects: 1609

Group type: COMPARATOR
Intervention: Unawareness of breast density
Number of subjects: 1609

Group type: COMPARATOR
Intervention: Poor breast density knowledge
Number of subjects: 1609
Study: 34147041

Group type: EXPERIMENTAL
Intervention: 500 mg capsules of Berberis vulgaris extract, twice daily for 4 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: 500 mg of starch capsules (placebo), twice daily for 4 weeks
Number of subjects: 52
Study: 32364800

Group type: EXPERIMENTAL
Intervention: Participants preferred a psychotherapist with personality characteristics similar to their own.
Number of subjects: 0
Study: 36153586

Group type: EXPERIMENTAL
Intervention: RinasciMENTE program (Internet-based self-help intervention based on CBT principles)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 128
Study: 32037857

Group type: EXPERIMENTAL
Intervention: Systematic exercise rehabilitation
Number of subjects: 166

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 166

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 166

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 166
Study: 32223373

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Medications (MEDs)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combination of CBT and MEDs (COMB)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 36102464

Group type: EXPERIMENTAL
Intervention: Performance tape (PT) with home exercise program for 4 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Classic tape (CT) with home exercise program for 4 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (C) with home exercise program for 4 weeks
Number of subjects: 39
Study: 34727951

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (AP)
Number of subjects: 1420

Group type: COMPARATOR
Intervention: No postoperative antibiotic prophylaxis (AP)
Number of subjects: 1420
Study: 32947390

Group type: EXPERIMENTAL
Intervention: Umezu polyphenols (800 mg/day for 12 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Umezu polyphenols
Number of subjects: 72
Study: 35288332

Group type: EXPERIMENTAL
Intervention: Cocoa extract (500 mg/d flavanols, including 80 mg (−)‐epicatechin) and multivitamin (Centrum Silver©)
Number of subjects: 21442

Group type: COMPARATOR
Intervention: Cocoa extract and multivitamin placebo
Number of subjects: 21442

Group type: COMPARATOR
Intervention: Multivitamin and cocoa extract placebo
Number of subjects: 21442

Group type: COMPARATOR
Intervention: Both placebos
Number of subjects: 21442
Study: 33417035

Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: MI
Number of subjects: 37

Group type: COMPARATOR
Intervention: NMES + MI
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study: 33004061

Group type: EXPERIMENTAL
Intervention: Malaria elimination readiness assessment (MERA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Training for health providers (HPs)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests (RDTs) availability
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Community health volunteers (CHVs) responsibilities
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Availability of anti-malarials among CHVs
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Data management and use
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Testing for malaria among patients with fever
Number of subjects: 35
Study: 35215483

Group type: EXPERIMENTAL
Intervention: School-based and family-based interventions with monthly monitoring for two consecutive semesters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific interventions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School-based and family-based interventions
Number of subjects: 0
Study: 35109633

Group type: EXPERIMENTAL
Intervention: Telehealth intervention; 31 dyads used telehealth methods to access the program.
Number of subjects: 63

Group type: COMPARATOR
Intervention: In-home visits; 32 dyads received visits in their own home.
Number of subjects: 63
Study: 32629391

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab (BE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erlotinib alone (E)
Number of subjects: 0
Study: 35532113

Group type: EXPERIMENTAL
Intervention: Custom mandibular advancement device (MAD) applied for 12 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Noncustom mandibular advancement device (MAD) applied for 12 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Self-reported outcomes for both custom and noncustom MADs
Number of subjects: 58
Study: 33417728

Group type: EXPERIMENTAL
Intervention: Baseline DTI parameters from 24 white matter tracts (WMTs)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Bilateral uncinate fasciculus
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Other WMTs in cingulum, cerebral and cerebellar peduncle, internal capsule, and corpus callosum
Number of subjects: 208
Study: 33865928

Group type: EXPERIMENTAL
Intervention: ENGAGE (engagement-focused behavioral therapy)
Number of subjects: 854

Group type: COMPARATOR
Intervention: UC (community-based usual care)
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Consistent medication use during behavioral therapy
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: ADHD+internalizing clinical profile
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Family adversity
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 854
Study: 33412570

Group type: EXPERIMENTAL
Intervention: Educational intervention (booklets on sleep apnea and sleep test)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 104
Study: 33316634

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 1977

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 1977

Group type: COMPARATOR
Intervention: CNS relapse
Number of subjects: 1977

Group type: COMPARATOR
Intervention: Overall survival post-relapse
Number of subjects: 1977

Group type: COMPARATOR
Intervention: Risk factors for CNS recurrence
Number of subjects: 1977
Study: 35571469

Group type: EXPERIMENTAL
Intervention: Simethicone + N-acetyl cysteine (NAC)
Number of subjects: 768

Group type: COMPARATOR
Intervention: Simethicone alone
Number of subjects: 768

Group type: COMPARATOR
Intervention: N-acetyl cysteine (NAC) alone
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study: 35248186

Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg twice per day
Number of subjects: 2044

Group type: EXPERIMENTAL
Intervention: Gefapixant 15 mg twice per day
Number of subjects: 2044

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2044
Study: 32889633

Group type: EXPERIMENTAL
Intervention: ACR-guided PCI
Number of subjects: 84

Group type: COMPARATOR
Intervention: OCT-guided PCI
Number of subjects: 84

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 84
Study: 33344050

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide for 3 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Observed controls (no active intervention)
Number of subjects: 33
Study: 33464334

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy alone (n=101)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Combined intravenous thrombolysis (alteplase at 0.6 mg/kg) plus mechanical thrombectomy (n=103)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy alone
Number of subjects: 204

Group type: COMPARATOR
Intervention: Combined intravenous thrombolysis plus mechanical thrombectomy
Number of subjects: 204
Study: 32164544

Group type: EXPERIMENTAL
Intervention: Lifestyle-based eHealth intervention
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indirect experiences of cognitive disorders
Number of subjects: 15
Study: 35772479

Group type: EXPERIMENTAL
Intervention: Parent-reported physical activity (PA)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Children meeting the PROMIS-PA 'good' cutoff
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Children's age
Number of subjects: 122
Study: 34456043

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 20
Study: 36239839

Group type: EXPERIMENTAL
Intervention: CB‐TDCS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: M1‐TDCS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study: 33730652

Group type: EXPERIMENTAL
Intervention: pemetrexed/pembrolizumab/platinum
Number of subjects: 405

Group type: COMPARATOR
Intervention: pemetrexed/placebo/platinum
Number of subjects: 405
Study: 32417961

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (ATE)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Adenopharyngoplasty (APP)
Number of subjects: 83
Study: 33123781

Group type: EXPERIMENTAL
Intervention: Puncture needles
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rasps
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 42
Study: 36352610

Group type: EXPERIMENTAL
Intervention: Arm and leg cycle ergometry along with conventional physiotherapy exercises
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional physiotherapy exercises
Number of subjects: 34
Study: 32710485

Group type: EXPERIMENTAL
Intervention: Postdivorce hostility levels
Number of subjects: 1856

Group type: EXPERIMENTAL
Intervention: Comparison of hostility levels between male and female divorcees
Number of subjects: 1856

Group type: EXPERIMENTAL
Intervention: Predictors of postdivorce hostility
Number of subjects: 1856
Study: 35550109

Group type: EXPERIMENTAL
Intervention: 30-minute running trial at -15°C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 90-minute running trial at -15°C
Number of subjects: 18
Study: 35690388

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 min, 15 daily sessions over 3 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 120
Study: 35320401

Group type: EXPERIMENTAL
Intervention: Polyphenol supplement (PPS) containing black tea powder, cocoa powder, and grape juice extract
Number of subjects: 14
Study: 34101212

Group type: EXPERIMENTAL
Intervention: Maternal thiamine supplementation (10 mg/day)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Maternal thiamine supplementation (0 mg/day)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Maternal thiamine supplementation (1.2 mg/day)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Maternal thiamine supplementation (2.4 mg/day)
Number of subjects: 335
Study: 35665277

Group type: EXPERIMENTAL
Intervention: Yishen Tiaodu acupuncture
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ordinary acupuncture
Number of subjects: 62
Study: 32042600

Group type: COMPARATOR
Intervention: G‐only intervention (online intervention for gambling)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: G + A intervention (online gambling intervention plus a brief personalized feedback intervention for unhealthy alcohol use)
Number of subjects: 282
Study: 35012796

Group type: EXPERIMENTAL
Intervention: Video instructions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paper handout instructions
Number of subjects: 60
Study: 33510561

Group type: EXPERIMENTAL
Intervention: Probiotics (mixed preparation of Bacillus subtilis and Enterococcus faecium)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 128
Study: 32089538

Group type: EXPERIMENTAL
Intervention: Sight word intervention for Deaf students (8-month duration)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sight word intervention for younger students
Number of subjects: 30
Study: 36430133

Group type: EXPERIMENTAL
Intervention: DenseNet169 model
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: MobileNetV3 model
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: VGG19 model
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ResNet50 model
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: VGG16 model
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: AlexNet model
Number of subjects: 500
Study: 34148161

Group type: EXPERIMENTAL
Intervention: XP‐endo Finisher (XPF)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Er,Cr: YSGG laser
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional endodontic needle (CEN)
Number of subjects: 64

Group type: COMPARATOR
Intervention: EndoActivator (EA)
Number of subjects: 64
Study: 35987678

Group type: EXPERIMENTAL
Intervention: NSAID (ibuprofen)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 34233640

Group type: EXPERIMENTAL
Intervention: IRE (Irreversible electroporation)
Number of subjects: 528

Group type: COMPARATOR
Intervention: SOC (Standard of Care)
Number of subjects: 528
Study: 33806518

Group type: EXPERIMENTAL
Intervention: CBT-based psychoeducation intervention (including mindfulness)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Psychoeducation plus biofeedback intervention
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control
Number of subjects: 225
Study: 35788072

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Peripheral iridectomy plus ab interno goniotomy
Number of subjects: 88
Study: 34169625

Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.6 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 32813861

Group type: EXPERIMENTAL
Intervention: High-monounsaturated fat meal (MUFA) (≈1000 kcal, 56.3% Energy from MUFA) with orange juice
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-saturated fat meal (SFA) (≈1000 kcal, 37.6% Energy from SFA) with orange juice
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-saturated fat meal (SFA) (≈1000 kcal, 37.6% Energy from SFA) with water
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-monounsaturated fat meal (MUFA) (≈1000 kcal, 56.3% Energy from MUFA) with water
Number of subjects: 39
Study: 35164686

Group type: EXPERIMENTAL
Intervention: PromeTheus program (home-based physical exercises and counseling services)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care with a one-time counseling session
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PromeTheus program
Number of subjects: 400
Study: 34724860

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided microwave ablation (MWA)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Parathyroidectomy (PTX)
Number of subjects: 167
Study: 33097492

Group type: EXPERIMENTAL
Intervention: Autocratising countries
Number of subjects: 136
Study: 35193510

Group type: EXPERIMENTAL
Intervention: Emergency obstetric care training (ALARM International Program)
Number of subjects: 577
Study: 33139072

Group type: EXPERIMENTAL
Intervention: Genetically predicted HSV infection
Number of subjects: 450581
Study: 33125193

Group type: EXPERIMENTAL
Intervention: Difficulty awakening
Number of subjects: 237627

Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 237627

Group type: COMPARATOR
Intervention: Migraine liability
Number of subjects: 237627
Study: 32715866

Group type: EXPERIMENTAL
Intervention: Telehealth intervention in pre-hospital and acute-care settings (n=11; 14.3%) for assessment and in rehabilitation and follow-up (n=61; 79.2%) for therapy delivery.
Number of subjects: 77
Study: 34158840

Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800 at low (50 mg) or high (100 mg) dose
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800 at high (100 mg) dose
Number of subjects: 11
Study: 34878625

Group type: EXPERIMENTAL
Intervention: LY-CovMab 30 mg, 150 mg, 600 mg, 1200 mg, 2400 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LY-CovMab 150 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LY-CovMab 600 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LY-CovMab 1200 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LY-CovMab 2400 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LY-CovMab
Number of subjects: 42
Study: 36050712

Group type: EXPERIMENTAL
Intervention: Sorafenib maintenance
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control (non-maintenance)
Number of subjects: 202
Study: 32770381

Group type: EXPERIMENTAL
Intervention: MP-MI/Physical lingual exercise (n = 8)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Physical lingual exercise (n = 7)
Number of subjects: 29

Group type: COMPARATOR
Intervention: MP-MI lingual exercise (n = 7)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo exercise (Control group, n = 7)
Number of subjects: 29
Study: 34016349

Group type: EXPERIMENTAL
Intervention: 10 min transition phase
Number of subjects: 9

Group type: COMPARATOR
Intervention: 20 min transition phase
Number of subjects: 9

Group type: COMPARATOR
Intervention: 45 min transition phase
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All transition phases (10, 20, 45 min)
Number of subjects: 9
Study: 33176460

Group type: EXPERIMENTAL
Intervention: MitraClip (TMVr)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Control (GDMT only)
Number of subjects: 614
Study: 35234160

Group type: EXPERIMENTAL
Intervention: Core Training Group (CTG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 24
Study: 32183772

Group type: EXPERIMENTAL
Intervention: COPe-support (digital mental health intervention)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Attention control (non-interactive online information resource pack)
Number of subjects: 360